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(PsA) patients: five tumour necrosis factor (TNF) an-
tagonists: adalimumab, etanercept, golimumab, cer-
tolizumab and infliximab; and the antagonist of the
shared p40 subunit of IL12 and IL23, ustekinumab1-15.
The oral small molecule inhibitor of phosphodiesterase
4, apremilast, has also been recently approved by the
European Medicines Agency and a position paper will
follow this recommendations regarding the use of
apremilast for the treatment of psoriatic arthritis16.  All
these agents have demonstrated clinical efficacy in pe-
ripheral arthritis, enthesitis, dactylitis, and skin/nail in-
volvement1-13, 17-21. Radiographic/structural progression
inhibition in erosive peripheral disease has also been
shown with TNF antagonists and ustekinumab9, 10, 22-26.
There is insufficient evidence about the use of TNF an-
tagonists in axial involvement of PsA patients (“psoria -
tic spondylitis”), with only one observational study
specifically reporting on spinal disease associated with
PsA27, 28. Therefore, the evidence for using TNF antago -
nists in axial involvement of PsA patients will be ex-
trapolated from trials in patients with ankylosing
spondylitis (AS)/axial spondyloarthritis (SpA), for
which there is extensive clinical efficacy data29-37. Pre-
liminary data on ustekinumab suggests symptomatic
improvement of axial disease38. 
Secukinumab is a potentially useful but not yet li-
censed biological therapy for this disease21,39,40. Abatacept
has also shown to be superior to placebo41. Results from
ixekizumab (phase 3), tofacitinib (phase 3) and
guselkumab are expected in the near future. The evidence
with the use of tocilizumab and rituximab is based in case
reports or open label studies, showing limited efficacy42.
The use of biological therapies in PsA is a rapi dly evol ving
field and the list of biologics used in PsA will have to be
regularly updated, as new data are published.
These treatment recommendations were formula ted
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AbstrAct
Objective:To update recommendations for the treatment
of psoriatic arthritis with biological therapies, endorsed
by the Portuguese Society of Rheumatology (SPR). 
Methods: These treatment recommendations were for-
mulated by Portuguese rheumatologists based on litera -
ture evidence and consensus opinion. At a national
meeting the 16 recommendations included in this
docu ment were discussed and updated. The level of
agreement among Portuguese Rheumatologists was as-
sessed using an online survey. A draft of the full text of
the recommendations was then circulated and sugges-
tions were incorporated. A final version was again cir-
culated before publication. 
Results: A consensus was achieved regarding the ini-
tiation, assessment of response and switching biologi-
cal therapies in patients with psoriatic arthritis (PsA).
Specific recommendations were developed for several
disease domains: peripheral arthritis, axial disease, en-
thesitis and dactylitis. 
Conclusion: These recommendations may be used for
guidance in deciding which patients with PsA should be
treated with biological therapies. They cover a rapidly
evolving area of therapeutic intervention. As more eviden -
ce becomes available and more biological thera pies are li-
censed, these recommendations will have to be updated. 
Keywords: Psoriatic Arthritis; Biological therapies;
Gui delines.
IntroductIon
There are currently six biological therapies licensed in
Europe for the treatment of active psoriatic arthritis
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by Portuguese rheumatologists based on literature ev-
idence and consensus opinion. Each recommendation
(Table I) was discussed by a group of rheumato logists
attending a national rheumatology meeting. The level
of agreement for each recommendation was asses sed
among all Portuguese rheumatologists using an online
survey, and measured on a 10-point numerical rating
scale (1=no agreement, 10=full agreement). 
Adalimumab, etanercept, golimumab, certolizu -
mab, infliximab and ustekinumab can be used for the
treatment of adults with active and progressive PsA
accor ding to the recommendations below. 
PsA is a heterogeneous and potentially severe disea -
se. It often presents with an overlap of subtypes and the
pattern of disease may vary over time. To make clini-
cal and treatment decisions easier, for the purpose of
these recommendations, we have differentiated four
major clinical phenotypes: 1) peripheral arthritis, 2)
axial disease, 3) enthesitis and 4) dactylitis. 
The treatment of skin/nail involvement in patients
with PsA is beyond the scope of these recommenda-
tions. The task force involved in developing these re -
commendations did not include dermatologists; there-
fore, the treatment of skin/nail involvement was not
addressed. However, it should be highlighted that the
assessment of skin/nail involvement in patients with
PsA, in collaboration with a dermatologist, should be
taken into account in the overall management of every
patient with PsA and in choosing the most adequate
therapy to achieve remission of both skin and muscu-
loskeletal manifestations. 
The aim of these recommendations is to provide a
tool that may guide clinicians in managing patients with
PsA and contribute to improving their care. It also aims
to increase the knowledge and awareness of PsA. Al-
though these recommendations contain some ori ginal
concepts, their general structure follows the pattern of
other international recommendations.  A structured na-
tional registry of patients with rheumatic disea ses, the
Rheumatic Diseases Portuguese Register (Reuma.pt) in-
corporating disease assessment tools has been created by
the Portuguese Society of Rheumatolo gy43. All patients
treated with biologic disease modi fying anti-rheumatic
drugs (DMARDs) should be re gistered in Reuma.pt.44
recommendAtIons for the use of 
bIologIcAl therAPIes In PAtIents wIth PsA 
dIAgnosIs
The patient should have a definitive diagnosis of PsA
made by a rheumatologist. Although several classifi-
cation criteria have been described, the ClASsification
criteria for Psoriatic ARthritis (CASPAR) have been
vali dated and are the most widely used criteria in in-
ternational recommendations and studies in PsA45,46. 
The five subgroups proposed by Moll and Wright are
still frequently used in clinical practice, although conside -
rable overlap between these groups is now recogni zed47. 
Despite no biological markers for PsA being availa -
ble, assays of rheumatoid factor and anti-citrullinated
protein antibodies (ACPA) may help in some cases in
the differential diagnosis with rheumatoid arthritis
(RA), although a positive result does not exclude a PsA
diagnosis. Power Doppler Ultrasound (PDUS) and/or
magnetic resonance imaging (MRI) may be useful to
help establishing the diagnosis, particularly in early
PsA, and for disease monitoring47,48.
RECOMMENDATION 1: A definitive diagnosis of PsA
requires the presence of validated criteria such as the
CASPAR or Moll and Wright criteria.
PerIPherAl ArthrItIs
In PsA, treatment with TNF antagonists or usteki -
numab is recommended for patients with active pe-
ripheral disease despite optimal treatment with con-
ventional synthetic (cs) DMARDs (treatment failure),
and if supported by the rheumatologist opinion.
dEfiniTiOn Of ACTivE PERiPhERAL ARThRiTis 
Published evidence has used tender and swollen joint
counts as a marker of disease activity. Counting the
number of tender and swollen joints is the key assess-
ment for peripheral arthritis, including PsA. The Ameri -
can College of Rheumatology (ACR) joint count of 68
tender and 66 swollen (68/66) and the modified 78/76
joint count are the most widely used methods. The 28-
joint count included in Disease Activity Score (DAS28)
used for the assessment of RA may not be appro priate
for all PsA patients, particularly in the oligoarticular
subtype and in patients with disease predominantly af-
fecting lower limb joints or the distal interphalangeal
joints49-53. Dedicated screens for joint counts as well as
DAS28 are available in Reuma.pt.  The presence of at
least one tender and/or swollen joint is generally acce -
pted as active peripheral disease1-13,17,53-55. Some poor
prognosis factors have been identified in PsA, namely
the number of actively inflamed joints (defined by some
authors as 5 or more), elevated acute phase reactants,
progressing radiographic damage, loss of physical func-
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tion and impairment of quality of life18,56.
RECOMMENDATION 2: Active peripheral arthritis can-
didate to biological therapy should be considered when
5 or more swollen joints (in a 66 joint count) are pre-
sent on two separate occasions, at least 1 month apart.
In patients with mono/oligoarthritis (1-4 swollen
joints), the decision to treat patients with biological
therapies should be made on a case-by-case basis, ac-
cording to the rheumatologist opinion, and taking into
account disease severity and the presence of poor prog-
nostic factors.
dEfiniTiOn Of TREATMEnT fAiLURE
Several good systematic literature reviews on the dif-
ferent disease-modifying therapies used for peripheral
PsA have been published18-20,57. In general, few ran-
domized controlled trials (RCTs) assessed the efficacy
of csDMARDs in PsA and many of the studies were of
poor quality. Although limited, some evidence exists,
based on some RCTs and observational studies, that
methotrexate, sulphasalazine, leflunomide, cyclos -
porine and even injected gold salts are effective in pe-
ripheral arthritis18-20. The use of intramuscular gold salts
is however not usually recommended because other
less toxic treatments are available. Although the level
of evidence is limited, methotrexate has been conside -
red as first choice csDMARD based on experts’ opi -
nion58,59. Regarding prevention of radiographic pro-
gression, csDMARD studies have either failed to docu-
ment it, had inconclusive results, or have not reported
it. To date, there is also no data showing that combi-
nation therapy with TNF antagonists and csDMARDs
is more efficacious than TNF antagonists’ monothera-
py. Furthermore it was not possible to conclude of an
additional benefit in adding MTX to TNF antagonists
in what concerns inhibition of radiographic progres-
sion26. However, data from registers suggests that the
association of MTX and TNF antagonists increases TNF
antagonists’ drug survival and that this effect is more
evident for infliximab60,61. 
Two RCTs showed efficacy of non-steroidal anti-in-
flammatory drugs (NSAIDs), including classic and cy-
clo-oxygenase-2 selective inhibitors, in reducing the
symptoms and signs of PsA. No difference in efficacy
between different NSAIDs was identified in compara-
tive studies18,59.
Although no evidence exists to support the use of
systemic corticosteroids in peripheral PsA, and despite
concerns over their safety in patients with psoriasis,
they are widely prescribed18-20,59. Intra-articular corti-
costeroids are also extensively used in clinical practice,
supported by few observational studies. A wise use of
intra-articular corticosteroids to treat persistent syno -
vitis of a given joint is recommended, particularly for
mono or oligoarthritis, or for bridging therapy whilst
waiting for other therapies to become effective59,62,63.
RECOMMENDATION 3: Biological therapy is recom-
mended for treatment of active peripheral arthritis in
patients who have failed to respond to at least one 
csDMARD (methotrexate or leflunomide) for at least 3
months on a standard (full) target dose, unless intole -
rance, toxicity or contraindication. In the absence of
poor prognostic factors, a second csDMARD (methotre -
xate, sulfasalazine, leflunomide, cyclosporine) or an as-
sociation of csDMARDs can be considered, with re-
assessment after 3 additional months of therapy. In case
of mono/oligoarthritis intra-articular corticosteroids
should also be considered. 
AssEssMEnT Of REsPOnsE TO TREATMEnT Of
ACTivE PERiPhERAL ARThRiTis
Unlike for RA, there are no validated and unequivo-
cally reliable instruments to evaluate response to thera -
py in PsA23,50,55,64-67. 
By analogy to clinical trials and previously published
recommendations, the definition of response to treat-
ment can be based in the psoriatic arthritis response
criteria (PsARC) or in the ACR response criteria8,65-67. To
obtain a PSARC response, a patient has to achieve ten-
der68 or swollen joint66 count improvement of 30% and
1 of the following:  patient global or physician global
improvement of at least 1 point on a 5-point Likert
scale. No worsening of any measure should occur66. To
achieve an ACR 20, 50, or 70 response, at least 20%,
50%, or 70% improvement in tender and swollen joint
counts and three of five scores of individual elements
[visual analog scale (VAS) scores of patient pain, physi-
cian and patient global assessment, a disability mea-
sure (Health Assessment Questionnaire - HAQ) and an
acute phase reactant (erythrocyte sedimentation rate -
ESR or C-reactive protein - CRP)] must be obtained
without worsening of the other two68. Furthermore, the
physician should base his decision on clinical, labora-
tory and radiological parameters of the disease66.
Response to treatment of “RA-like” PsA (i.e. PsA with
a pattern of joint involvement similar to RA) may be as-
sessed using criteria developed for RA, such as the
DAS28 and the European League Against Rheumatism
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(EULAR) response criteria, shown to be reliable and dis-
criminative in this subtype of PsA67,69,70. Patients with
distal interphalangeal joint or oligoarticular involvement
should not be considered as “RA-like” PsA and the
DAS28 should not be used in this subgroup of patients53.
Composite measures evaluating the different do-
mains of psoriatic disease have been developed such
as the psoriatic arthritis disease activity score (PAS-
DAS), the composite psoriatic arthritis disease activity
score (CPDAI), the arithmetic mean of the desirable
function (AMDF), the psoriatic arthritis joint activity
index (PsAJAI) and the disease activity index for pso-
riatic arthritis (DAPSA), but their validity and discrimi -
native capacity are still being assessed71. An effort for
the definition of cut-offs for low, moderate and high
disease activity for PASDAS, CPDAI, DAPSA and
DAS28-CRP has been undertaken72. Finally, minimal
disease activity (MDA) has been defined, and tender
and swollen joint counts ≤1 based on 68 tender/66
swollen joint counts have been included as two of the
domains. An MDA is attained if 5/7 of the following are
achieved: tender joint count ≤1, swollen joint count
≤1; psoriasis activity and severity index (PASI) ≤1 or
body surface area (BSA) ≤3 patient pain VAS score of
≤15; patient global disease activity VAS score of ≤20;
HAQ score ≤0.5 and tender entheseal points ≤173. 
RECOMMENDATION 4: For peripheral arthritis, res -
ponse should be defined by PsARC / ACR criteria. The
rheumatologist opinion and other clinical, laboratorial
and radiological parameters should be considered in the
decision to maintain or stop treatment. Response should
be assessed at 3 and then 6 months after starting bio-
logical therapy. In patients with “RA-like” di sease, res -
ponse may also be determined according to changes in
the DAS28: response defined by an improvement of at
least 0.6 units at 3 months, and greater than 1.2 units
at 6 months. The maintenance of treatment beyond that
period, despite failure to achieve response, should be
done according to the rheumatologist opinion. 
AxIAl dIseAse 
In PsA, treatment with TNF antagonists is recom-
mended for patients with active axial disease despite
optimal conventional treatment (treatment failure), and
if supported by the rheumatologist opinion.  Uste -
kinumab and secukinumab have shown promising re-
sults in AS/axial SpA but have not been approved for
this disease yet. Since the evidence for treating “psoria -
tic spondylitis” is extrapolated from AS/axial SpA trials,
other drugs than TNF antagonists should only be con-
sidered to specifically treat the axial component of PsA
once they have been approved by regulatory agencies
to treat AS/axial SpA. Specific trials in “psoriatic
spondylitis” are unlikely to be performed.
dEfiniTiOn Of AxiAL invOLvEMEnT
There is currently no consensus about the definition of
“axial involvement” of patients with PsA (“psoriatic
spondylitis”)74. The combination of inflammatory back
pain and at least bilateral grade II or unilateral grade III
sacroiliitis has been often used to define axial involve-
ment is PsA, reflecting an adaptation of the modified
New York (mNY) criteria for AS23, 75-77. The more re-
cently developed Assessment of Spondyloarthritis In-
ternational Society (ASAS) classification criteria for 
axial SpA allow classifying patients with early disease,
in the absence of radiographic sacroiliitis78, 79. The over-
lap of classification criteria between AS/axial SpA and
“psoriatic spondylitis” has been supported by studies
that found no differences in disease activity, function
and quality of life between AS patients with and with-
out psoriasis80, 81. 
RECOMMENDATION 5: Patients with PsA are classified
as having axial disease if they also fulfill the ASAS classi-
fication criteria for axial SpA or the mNY criteria for AS.
dEfiniTiOn Of ACTivE AxiAL disEAsE 
There is no specific tool to assess disease activity of the
axial involvement in PsA82-84. Therefore, assuming simi -
lar responses to therapy, the use of the same instruments
of AS has been recommended for axial PsA: the Bath
Ankylosing Spondylitis Disease Activity Index (BAS-
DAI) and the Ankylosing Spondylitis Disease Acti vi ty
Score (ASDAS), including ASDAS validated cut-offs (an
ASDAS ≥2.1 represents high disease activity)83-88. Im-
portantly, in a study of PsA patients with axial involve-
ment, the ASDAS performed equally well as the BAS-
DAI82.
There is also recent evidence that the ASDAS may
better reflect the inflammatory disease processes in pa-
tients with axial SpA and that ASDAS high disease ac-
tivity (ASDAS ≥2.1) may be a better cut-off than BAS-
DAI elevation (BASDAI ≥4) to select patients for treat-
ment with TNF antagonists, namely because it selects
a higher number of patients with characteristics pre-
dictive of good response to these therapies89-91. 
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Dedicated screens to register axial disease activity
are available in Reuma.pt.44
Additionally, the decision to consider the disease as
active should be supported by the rheumatologists
opinion, who should base his/her judgment on clinical,
laboratorial (acute phase reactants) and imaging (ra-
diographs, MRI) features of the disease.
RECOMMENDATION 6: Active axial disease candidate
to biological treatment is defined by a BASDAI ≥4 or
ASDAS ≥2.1, in two separate occasions, with at least 1
month interval and a positive opinion from the
rheumatologist.
dEfiniTiOn Of TREATMEnT fAiLURE Of ACTivE
AxiAL disEAsE
NSAIDs (classical or COX-2 inhibitors) have demons -
trated clinical efficacy in axial disease, contrary to 
csDMARDs92. All patients should have an adequate
therapeutic trial of at least two NSAIDs before starting
biologic therapies. The literature about the length of
time beyond which it would be unlikely that an NSAID
would be effective is scarce. Only a few trials provided
detailed information on the time course of efficacy and
these suggest that the maximum effect is achieved af-
ter 2 weeks in AS patients93, 94. For clinical purposes
most guidelines have considered a period of 1 to 3
months of NSAIDs for the definition of treatment failu -
re95-98.   
RECOMMENDATION 7: Treatment failure in axial
disea se is defined as active disease despite a continuous
therapeutic trial with at least two NSAIDs over 1-3
months, at maximum recommended or tolerated do ses,
unless contraindicated.  
AssEssMEnT Of REsPOnsE TO TREATMEnT
The choice of at least a 3-month interval as the time for
evaluation of response to a biological agent was based
on observations from phase III trials of TNF antago-
nists, where response rates stabilized from 12 weeks
onwards. The inclusion of the ASDAS response as an
alternative to the BASDAI response in assessing effica-
cy of the biological therapy was based on the improved
metric properties of the ASDAS compared to the BAS-
DAI and its wide acceptance86,88,91,99. Specific measures
of treatment response for axial PsA are being studied
but until their full validation, BASDAI and ASDAS res -
ponse criteria were selected as adequate tools. 
The initial RCTs of infliximab, adalimumab, etaner-
cept and golimumab did not assess specifically axial
disease in PsA. The more recently studies of cer-
tolizumab efficacy in axial SpA showed significant im-
provement of ASAS20 but patients with psoriasis were
not defined as a group100. Ustekinumab showed nu-
merical improvements of BASDAI in PsA patients with
axial disease but this was a sub-analysis in a small sub-
set of patients, as the trial was not designed to assess ef-
ficacy in this subpopulation of PsA patients37,40,101. 
RECOMMENDATION 8: Response to treatment should
be assessed after at least 3 months of continuous treat-
ment with a biological therapy. Response criteria are: 1)
a decrease in BASDAI ≥50% or ≥2 units (0-10) or 2) a
decrease in ASDAS ≥1.1 units.
enthesItIs
In PsA, treatment with TNF antagonists or ustekinu -
mab is recommended for patients with active enthesi-
tis despite optimal conventional treatment (treatment
failure), and supported by the rheumatologist opinion.
defInItIon of enthesItIs
The diagnosis of enthesitis is challenging and several
instruments proposed for clinical assessment have been
tested but no single one has gained widespread accep-
tance50,65,66,102. Clinical examination is based on pain,
tenderness and swelling at tendons, ligaments or capsu -
les bone insertion. Although the term enthesitis pre-
supposes inflammation of the entheseal site, differential
diagnosis with non-inflammatory enthesopathy can be
difficult. To support the rheumatologist’ opinion, both
PDUS and MRI can be used and several studies have
documented a good correlation with the current “gold
standard”, which is the clinical examination103-107.
RECOMMENDATION 9: In patients with PsA, the diag-
nosis of enthesitis should be established on clinical
grounds. PDUS or MRI can be used to support the diag -
nosis.
dEfiniTiOn Of ACTivE EnThEsiTis 
There are several tools to assess enthesitis namely the
Modified Mander Enthesitis Index, the Maastricht AS
enthesitis score (MASES) and its PsA modified version,
including the plantar fascia, the Leeds Enthesitis Index
(LEI) and the SpA research consortium of Canada (SPAR-
CC) score108-113. Up to now there is still no consensus on
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the preferable index to use in clinical practi ce, although
the LEI has been the only developed and va lidated
specifically for PsA113. In TNF antagonists and usteki -
numab RCTs, several of these tools have been used to
assess the burden of enthesitis: the number of patients
with enthesitis3-6,13,17,114, severity scores5,6,13,37,101,115 and an
MRI score116. 
The number of enthesitis sites, pain intensity (VAS
or NRS) and the repercussion on function (HAQ) have
been used to quantify disease severity. Olivieri et al used
the criteria of a patient global assessment greater than
40 mm (0-100 VAS) and entheseal pain greater than 2
in a 0-4 Likert scale to define active enthesitis. In the
more comprehensive GRAPPA guidelines, severe di -
sease was defined as pain on palpation of >2 entheses
and/or functional impairment according to the physi-
cian, while in the CPDAI the criteria for severe disease
was pain on palpation of >3 entheses and functional
disability according to the patient (HAQ≥0.5)41,113,116.
However, these criteria still require further validation
in RCTs and longitudinal observational studies. To de-
fine activity, in case of diagnostic doubt, either PDUS
or MRI can also be helpful.(48) Most published guide-
lines state that enthesitis should be treated as a separate
entity and, until further trial data become available, TNF
antagonists and ustekinumab therapy for PsA entheseal
disease should be decided on an individual basis117.
RECOMMENDATION 10: Active enthesitis should be
defined on a clinical basis, using a validated enthesitis
index and the rheumatologist opinion, taking into ac-
count the impact of enthesitis in activities of daily life,
physical function and quality of life. PDUS or MRI can
be used to assist the rheumatologist opinion.
dEfiniTiOn Of TREATMEnT fAiLURE
Traditionally the conventional treatment for enthesitis
includes NSAIDs, glucocorticoid injections and phy -
sical therapy, although, in fact, their efficacy has not
been properly studied55,58,116,118-120. There is also a subs -
tantial lack of evidence on the use of csDMARDs and
up to now they have shown little effect on enthesi-
tis58,119-121. TNF antagonists, as a class, and ustekinu -
mab are therefore considered effective therapies for the
treatment of enthesitis in PsA3-7,13,17,27,37,101,114,115,120. Se -
veral limitations preclude conclusions regarding dif-
ferences of efficacy between TNF antagonists or in com-
parison with ustekinumab: 1) different outcome mea-
sures used in RCTs, 2) lack of head-to-head studies, 3)
limitations of study design, 4) absence of adequately
powered studies for this endpoint.
There is no consensus for the definition of treatment
failure in PsA enthesitis. Olivieri et al defined treatment
failure as lack of response to at least 2 NSAIDs for at
least 3 months and lack of response to at least two
steroid injections27. In the HEEL study (etanercept),
treatment failure was defined as lack of response to full
dose NSAIDs for at least 3 months116. Furthermore, in
the main TNF antagonist trials there were no specific
references to criteria for failure to standard therapy in
enthesitis. Therefore, in the absence of evidence for the
use of csDMARDs, both TNF antagonists and uste -
kinumab can be considered for the treatment of per-
sistent, active, refractory enthesitis, if there is significant
impact on physical function and quality of life based on
the rheumatologist opinion55, 122, 123. 
RECOMMENDATION 11: Biological therapy is recom-
mended for patients with persistent (at least 3 months)
active enthesitis, who have failed to respond to NSAIDs
(in full therapeutic or tolerated doses, unless con-
traindicated) and local corticosteroids injections (if ap-
plicable and not contra-indicated). 
AssEssMEnT Of REsPOnsE TO TREATMEnT 
fOR PATiEnTs wiTh PERsisTEnT (AT LEAsT 
3 MOnThs) ACTivE EnThEsiTis
There are no validated thresholds for the commonly
used enthesitis indexes in PsA to evaluate treatment
res ponse in PsA enthesitis. For the new composite in-
dexes that include enthesitis assessment, such as the
PASDAS and CPDAI, the defined cutoffs are consi dered
for the whole score72. Minimal disease activity consi ders
that the enthesitis domain has ≤ 1 tender entheses from
a maximum of 13, allowing any of the available enthe-
sitis outcome measures to be used73.
Based in these limitations, response to treatment can
be judged on the basis of the decrease in either the
number of active enthesitis sites and/or in the degree of
impairment (which could be defined by a reduction of
HAQ score)13. Some investigators have suggested that
the minimal clinically important difference in the HAQ
score is 0.22124. However, such cut-off has never been
validated in PsA. Besides clinical methods, PDUS and
MRI have shown to be reproducible methods for moni -
toring therapeutic response in enthesitis of SpA116,125.
By analogy to data from RCTs, although not speci -
fically for enthesitis, at least 3 to 6 months should be
proposed for initial evaluation of TNF antagonist or
ustekinumab efficacy for the treatment of enthesitis. 
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RECOMMENDATION 12: Assessment of response
should be a continuous process. Patients are conside -
red as responders to treatment if, within 3 to 6 months,
there is a reduction in the number of active enthesitis
sites or a reduction in functional impairment. The de-
cision to continue treatment should be supported by
the rheumatologist opinion. PDUS or MRI can be used
to assist the decision.
dActylItIs 
In PsA, treatment with TNF antagonists or ustekinu -
mab is recommended for patients with active dactyli-
tis, despite optimal conventional treatment (treatment
fai lure), and supported by the rheumatologist opinion.
defInItIon of dActylItIs
There are several definitions of dactylitis that integrate
the concept of swelling of a digit, usually due to a com-
bination of synovitis, tenosynovitis and enthesitis to-
gether with soft-tissue oedema55,126,127. 
Although there is no uniformity in the methods used
for diagnosing dactylitis, clinical assessment based on
inspection and palpation constitutes, up to now, the
“gold standard”. Based on the two scores developed to
define dactylitis activity, the dactylitis severity score
(DSS) and the Leeds dactylitis index (LDI), dactylitis
can be defined as a DSS score higher than 1 or a digi-
tal circumference >10% compared to the contra late ral
finger for the LDI, respectively5,128. Furthermore, ima -
ging methods such as PDUS and MRI may improve
diag nostic accuracy and severity evaluation129,130.
RECOMMENDATION 13: In patients with PsA, the
diagno sis of dactylitis should be established on clinical
grounds based on the swelling of a whole digit. PDUS
or MRI can be used to support the diagnosis.
dEfiniTiOn Of ACTivE dACTyLiTis 
Active dactylitis is defined based on physical examina-
tion as a swollen digit, although PDUS/MRI can be used
for confirmation.
Most guidelines assess dactylitis as an “active” joint.
The distinction between “active or tender” and “inac-
tive or non-tender” has prognostic impact as active
dactylitis is associated with a higher risk of developing
local erosions131. Some clinical trials used a simple
count of fingers with dactylitis21, 121, while others used
severity scores such as the DSS2,3,5,17,37,101,132 and the
LDI115. The DSS grades severity from 0 to 35. The LDI
assesses severity based on two parameters: digital cir-
cumference in the proximal phalange (tumefaction)
and a 0-3 tenderness score resembling the Ritchie In-
dex128. In the CPDAI composite index, dactylitis was
assessed by using a simple digit count and 3 grades:
mild (≤3 digits; normal function), moderate (≤3 digits
but function impaired; or >3 digits but normal func-
tion) and severe (>3 digits and function impaired, de-
fined as an HAQ score >0.5)133. In the PASDAS the
number of tender dactylitis was also included72. For
routine clinical practice, simple tender dactylitic fin-
gers count is possibly the most feasible tool to define
active disease and monitor patients.
RECOMMENDATION 14: Active dactylitis should be
defined on a clinical basis, according to the rheuma-
tologist opinion, taking into account swelling and ten-
derness, and the impact of dactylitis in daily life acti -
vities, physical function and quality of life. PDUS or
MRI can be used to assist the decision.
dEfiniTiOn Of TREATMEnT fAiLURE Of ACTivE
dACTyLiTis
The treatment of dactylitis is largely empirical. Treat-
ment strategies include NSAIDs, steroid injections, cs-
DMARDs, TNF antagonists and ustekinumab. NSAIDs
and steroids injections have not been properly studied
but are often used as first line treatment. There is also
a substantial lack of evidence of efficacy of csDMARDs
and there is no evidence that any of these drugs actual -
ly prevent disease progression. 
Conversely, TNF antagonists, including etanercept,
infliximab, adalimumab, certolizumab and golimu -
mab, and the IL-12 and IL-23 blocker ustekinumab,
have shown promising results in dactylitis, although
dactylitis has not been assessed as a primary endpoint
in these trials3-7,13,17,115. 
There is no international consensus on the definition
of treatment failure even if many authors consider re-
fractoriness to NSAIDs and corticoids injec-
tions54,55,123,134. Olivieri et al defined treatment failure as
the lack of response to at least 2 NSAIDs for >3 months
and at least two steroid injections27. In the main TNF an-
tagonists’ trials, there was no reference to criteria defin-
ing treatment failure in dactylitis. Further, in most
guidelines, dactylitis is not separately addressed and is
usually analyzed together with peripheral arthritis134-136.
Although there is scarce evidence to support the use
of csDMARDs in dactylitis, they are commonly used,
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namely in the context of concomitant peripheral active
disease137. Considering the component of joint synovi-
tis, often observed in dactylitis, most rheumatologists
still feel that patients should have an adequate trial of
csDMARDs, before progressing to treatment with bio-
logical therapy, until further evidence is available. In
selected cases, namely when severe and erosive disease
is observed, biologic therapies can be considered before
csDMARDs. 
RECOMMENDATION 15: Biological therapy is recom-
mended for patients with persistent (at least 3 months)
active dactylitis who have failed to respond to NSAIDs
(in full therapeutic or tolerated doses, unless contra-in-
dicated), csDMARD therapy and at least two local cor-
ticosteroids injections, when applicable.
AssEssMEnT Of REsPOnsE TO TREATMEnT Of
ACTivE dACTyLiTis
In the absence of validated measures, the reduction in
the number of digits with dactylitis, the reduction on
dactylitis scores and the improvement in functional
scores or in composite scores are some of the outcome
measures that have been proposed and can be consi -
dered to assess response. MDA includes the dactylitis
domain requiring ≤ 1 dactylitis as a criterion73. By ana -
logy with the assessment of response of peripheral
arthritis used in TNF antagonists’ trials, the time for as-
sessment of response should be at least 3 months, with
the possibility of a 3-month extension4-7,13,17,114. It is im-
portant to keep in mind that, in both TNF antagonist
and ustekinumab long-term follow-up trials, a pro-
gressive improvement of dactylitis scores up to 52
weeks was depicted. Therefore, for responders, further
improvement beyond 24 weeks can be expected101,132. 
RECOMMENDATION 16: Assessment of response of ac-
tive dactylitis should be performed at three months.
Patients are considered responders to treatment if there
is a reduction in the number of digits with active
dactylitis and a reduction in functional impairment.
The decision to continue treatment should be sup-
ported by the rheumatologist opinion. PDUS or MRI
can be used to assist the decision.
swItchIng And tAPerIng bIologIcAl 
therAPIes
After an adequate dose and length of treatment, non-
responders are recommended to switch to another bio -
logical therapy. The evidence in this area is still scarce
and mainly based on registry data. Even though res -
ponses might be slightly lower, there are sustained and
good response rates to a second or third TNF antago-
nist, supporting switching recommendations138-143.
Drug survival is also reduced with the number of
switches139,140,142. Dose increase of biological treatments,
in case of treatment failure, is not advised. 
In case of a good response to biological therapy there
is also still little evidence for recommending a dose re-
duction or the interruption of the treatment, with the
latest being associated with high rates of flare144. How-
ever, tapering biological DMARDs, expanding the inter-
val between doses or reducing the dose, may be conside -
red in individualized cases (eg. remission for at least 12
months in the absence of steroid or regular NSAID treat-
ment), according to the rheumatologist opinion (and po-
tentially supported by imaging methods), and especial-
ly if the treatment is being combined with a csDMARD144.
fInAl remArks 
PsA is a multidomain disease characterized by in-
volvement of peripheral joints, spine, enthesis, dactyli-
tis, skin/nails and other extra-articular sites. However,
even the isolated presence of monoarthritis, enthesitis
or dactylitis may be severe enough to seriously limit
the patient’s quality of life, working or leisure capabi -
lity. In this context, if conventional treatment fails, the
rheumatologist opinion is essential for the decision to
start biological therapy, as highlighted in the above re -
commendations. A key aspect of treatment is accurate
diagnosis and assessment, which facilitates the institu-
tion of appropriate treatment in a timely fashion. Diag -
nosing, as early as 6 months after symptoms onset, is
recognized as fundamental to improve radiographic
and functional outcomes and should be aimed in rou-
tine clinical practice145. 
MDA criteria for patients with PsA have been de-
fined and validated and constitute a relevant outcome
measure to assess effectiveness64,146,147. Treat to target
recommendations in spondyloarthritis including PsA
aiming at maximising long-term health related quality
of life and social participation through rapid control of
signs and symptoms, prevention of structural damage,
normalisation or preservation of function, avoidance
of toxicities and minimisation of comorbidities have
been recently developed and should be taken into ac-
count in the global management of PsA patients. Simi -
larly, recommendations for the use of imaging in the
diagnosis of spondyloarthritis in clinical practice were
established148,149.
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tAble I. recommendAtIons for the use of bIologIcAl therAPIes In PAtIents wIth PsorIAtIc 
ArthrItIs
Agreement
Domain Recommendations mean (SD)
Recommendation 1
A definitive diagnosis of PsA requires the presence of validated criteria such as the CASPAR 7.9 (2.0)
or Moll and Wright criteria.
Recommendation 2
Active peripheral arthritis candidate to biological therapy should be considered when 5 8.5 (1.6)
or more swollen joints (in a 66 joint count) are present on two separate occasions, at least 1
month apart. In patients with mono/oligoarthritis (1-4 swollen joints), the decision to treat
patients with biological therapies should be made on a case-by-case basis, according to the 
rheumatologist opinion, and taking into account disease severity and the presence of 
poor prognostic factors.
Recommendation 3
Biological therapy is recommended for treatment of active peripheral arthritis in patients 8.8 (1.5)
who have failed to respond to at least one csDMARD (methotrexate or leflunomide) for at 
least 3 months on a standard (full) target dose, unless intolerance, toxicity or 
contraindication. In the absence of poor prognostic factors, a second csDMARD 
(methotrexate, sulfasalazine, leflunomide, cyclosporine) or an association of csDMARDs 
can be considered, with reassessment after 3 additional months of therapy. In case of 
mono/oligoarthritis intra-articular corticosteroids should also be considered. 
Recommendation 4
For peripheral arthritis, response should be defined by PsARC / ACR criteria. The 8.6 (1.3)
rheumatologist opinion and other clinical, laboratorial and radiological parameters should 
be considered in the decision to maintain or stop treatment. Response should be assessed at 
3 and then 6 months after starting biological therapy. In patients with “RA-like” disease, 
response may also be determined according to changes in the DAS28: response defined by 
an improvement of at least 0.6 units at 3 months, and greater than 1.2 units at 6 months. 
The maintenance of treatment beyond that period, despite failure to achieve response, 
should be done according to the rheumatologist opinion. 
Recommendation 5
Patients with PsA are classified as having axial disease if they also fulfill the ASAS 8.9 (1.7)
classification criteria for axial SpA or the mNY criteria for AS.
Recommendation 6
Active axial disease candidate to biological treatment is defined by a BASDAI ≥4 or 8.9 (1.5) 
ASDAS ≥2.1, in two separate occasions, with at least 1 month interval and a positive 
opinion from the rheumatologist.
Recommendation 7
Treatment failure in axial disease is defined as active disease despite a continuous 8.7 (1.4)
therapeutic trial with at least two NSAIDs over 1-3 months, at maximum recommended 
or tolerated doses, unless contraindicated.  
Recommendation 8
Response to treatment should be assessed after at least 3 months of continuous treatment 8.9 (1.3)  
with a biological therapy. Response criteria are: 1) a decrease in BASDAI ≥50% or 
≥2 units (0-10) or 2) a decrease in ASDAS ≥1.1 units. 
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tAble I. (continuation)
Agreement
Domain Recommendations mean (SD)
Recommendation 9
In patients with PsA, the diagnosis of enthesitis should be established on clinical 9.0 (1.1)
grounds. PDUS or MRI can be used to support the diagnosis.
Recommendation 10
Active enthesitis should be defined on a clinical basis, using a validated enthesitis index 8.8 (1.3)
and the rheumatologist opinion, taking into account the impact of enthesitis in activities 
of daily life, physical function and quality of life. PDUS or MRI can be used to assist the 
rheumatologist opinion.
Recommendation 11
Biological therapy is recommended for patients with persistent (at least 3 months) active 8.2 (1.7)
enthesitis, who have failed to respond to NSAIDs (in full therapeutic or tolerated doses, 
unless contraindicated) and local corticosteroids injections (if applicable and not 
contra-indicated). 
Recommendation 12
Assessment of response should be a continuous process. Patients are considered as 8.7 (1.3)
responders to treatment if, within 3 to 6 months, there is a reduction in the number of 
active enthesitis sites or a reduction in functional impairment. The decision to continue 
treatment should be supported by the rheumatologist opinion. PDUS or MRI can be used 
to assist the decision.
Recommendation 13
In patients with PsA, the diagnosis of dactylitis should be established on clinical grounds 9.4 (0.8)
based on the swelling of a whole digit. PDUS or MRI can be used to support the diagnosis.
Recommendation 14
Active dactylitis should be defined on a clinical basis, according to the rheumatologist 9.1 (1.1)
opinion, taking into account swelling and tenderness, and the impact of dactylitis in daily 
life activities, physical function and quality of life. PDUS or MRI can be used to assist 
the decision.
Recommendation 15
Biological therapy is recommended for patients with persistent (at least 3 months) active 8.4 (1.7)
dactylitis who have failed to respond to NSAIDs (in full therapeutic or tolerated doses, 
unless contra-indicated), csDMARD therapy and at least two local corticosteroids 
injections, when applicable.
Recommendation 16
Assessment of response of active dactylitis should be performed at three months. Patients 8.7 (1.3)
are considered responders to treatment if there is a reduction in the number of digits 
with active dactylitis and a reduction in functional impairment. The decision to continue 
treatment should be supported by the rheumatologist opinion. PDUS or MRI can be used 
to assist the decision.
Enthesitis
Dactylitis
Agreement was voted on a scale from 1 to 10 (fully disagree to fully agree) by 73 voting rheumatologists through an online survey.
PsA, Psoriatic Arthritis. CASPAR, ClASsification criteria for Psoriatic ARthritis. csDMARD, conventional synthetic disease modifying
antirheumatic drug. PsARC, Psoriatic Arthritis Response Criteria. ASAS, Assessment of Spondyloarthritis international Society. 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. ASDAS, Ankylosing Spondylitis Disease Activity Score. MRI, magnetic
resonance imaging. SD, standard deviation. PDUS, power Doppler ultrasound. DAS28, Disease Activity Score 28-joint count.
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Factors such as patient preference for the type and
frequency of treatment administration, treatment com-
pliance and potential adverse events should also be ta -
ken into account when treating a patient with PsA. Im-
portantly, safety should not be underestimated. The pre-
liminary workup to initiate treatment with TNF antago -
nists and ustekinumab in PsA patients should follow
the same principles and recommendations as for
RA150,151. Patients with latent tuberculosis should receive
appropriate prophylactic therapy as recommen ded152,153.
In addition, immunization records should be checked
for compliance with recommended vaccinations. 
Given the complex array of clinical features in PsA,
treatment guidelines based in individual domains may
result in an underestimation of the extent of disease.
When assessing a patient with PsA the overall burden
of disease should also be taken into account. It is there-
fore of great importance to consider the impact of the
disease as a whole on an individual’s physical function,
work disability, health and quality of life. Several com-
posites indexes have been recently developed (CPDAI,
PASDAS and AMDF) and for some their respective cut-
offs were defined but its broad use and implementation
in treatment guidelines is not yet established133,154-156. In
the absence of a validated composite tool to select pa-
tients for biological treatment, the rheumatologist opi -
nion is of utmost importance to identify patients in
which the overall disease burden justifies this treatment.
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